Search results

Found 4 releases mentioning: acceleron

Business Wire Australia and New Zealand

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

03 Dec 2018

Business Wire Australia and New Zealand

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

02 Dec 2018

Business Wire Australia and New Zealand

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

10 Jul 2018

Business Wire Australia and New Zealand

Cerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases

02 Dec 2016

Display

Sort by

Your saved searches

If you regularly search for a topic or keyword, you can save the current search criteria for quick access in future. Saved searches will be listed here.

Search results

Found 4 releases mentioning: acceleron

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Cerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases

Display

Your saved searches

Refine results

Mentioning

Date published

Topics

Save this search